Korst Robert J, Fernando Sumudinie, Catlin Ann Christine, Rutledge John R, Girard Nicolas, Huang James, Detterbeck Frank
Department of Thoracic Surgery, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, New York, New York; Valley/Mount Sinai Comprehensive Cancer Care, Paramus, New Jersey.
Rosen Center for Advanced Computing, Purdue University, West Lafayette, Indiana.
Ann Thorac Surg. 2017 Dec;104(6):1815-1820. doi: 10.1016/j.athoracsur.2017.06.053. Epub 2017 Oct 21.
Positron emission tomography may have a role in the pretreatment workup of patients with thymic malignancies. This study was undertaken to determine the utility of the maximum standardized uptake value (SUV) in predicting histologic type and tumor stage in a large cohort of thymic epithelial tumors.
The large, multiinstitutional, prospective database of The International Thymic Malignancy Interest Group (ITMIG) was queried for the use of positron emission tomography in the pretreatment workup of patients with thymic tumors. Data analyzed included demographics, SUV, histologic tumor type, and tumor stage. The distribution of SUV according to histologic type and Masaoka-Koga pathologic stage was determined, and the ability of SUV to predict these two variables was calculated using analysis of receiver operating characteristic curves.
Since 2012, data from 926 patients with thymic malignancies were entered into the ITMIG prospective database, of which 154 had a reported value for SUV. The area under the receiver operating characteristic curve for SUV in predicting histologic type and pathologic stage was 0.79 (95% confidence interval, 0.70 to 0.88; p < 0.001) and 0.81 (95% confidence interval, 0.73 to 0.88; p < 0.001), respectively. In addition, there was a significant relationship between SUV and histologic type (p < 0.001) as well as Masaoka-Koga pathologic stage (p < 0.001).
Positron emission tomography has utility in predicting clinicopathologic features of thymic malignancies. These results may have clinical application in the pretreatment workup of patients with these rare tumors.
正电子发射断层扫描在胸腺恶性肿瘤患者的预处理检查中可能发挥作用。本研究旨在确定最大标准化摄取值（SUV）在预测一大群胸腺上皮肿瘤的组织学类型和肿瘤分期方面的效用。
查询国际胸腺恶性肿瘤兴趣小组（ITMIG）的大型多机构前瞻性数据库，以获取正电子发射断层扫描在胸腺肿瘤患者预处理检查中的使用情况。分析的数据包括人口统计学、SUV、组织学肿瘤类型和肿瘤分期。确定了根据组织学类型和Masaoka-Koga病理分期的SUV分布，并使用受试者操作特征曲线分析计算SUV预测这两个变量的能力。
自2012年以来，926例胸腺恶性肿瘤患者的数据被录入ITMIG前瞻性数据库，其中154例报告了SUV值。SUV预测组织学类型和病理分期的受试者操作特征曲线下面积分别为0.79（95%置信区间，0.70至0.88；p<0.001）和0.81（95%置信区间，0.73至0.88；p<0.001）。此外，SUV与组织学类型（p<0.001）以及Masaoka-Koga病理分期（p<0.001）之间存在显著关系。
正电子发射断层扫描在预测胸腺恶性肿瘤的临床病理特征方面具有效用。这些结果可能在这些罕见肿瘤患者的预处理检查中具有临床应用价值。
